QGEN News and Press, Qiagen N.V. From 11/19/25

2025-11-19 12:23:26 ET Qiagen N.V. (QGEN) Jefferies London Healthcare Conference 2025 November 19, 2025 5:30 AM EST... Read the full article on Seeking Alpha For further details see: Qiagen N.V. (QGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-17 15:07:09 ET Qiagen N.V. (QGEN) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 12:40 PM EST... Read the full article on Seeking Alpha For further details see: Qiagen N.V. (QGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

2025-11-13 09:40:32 ET Back in March of this year, we talked at length about applications of AI to the drug discovery process in the context of Recursion Pharmaceuticals ( RXRX ). During that conversation, we mentioned another AI healthcare name in passing that has stuck in our ...

QIAsymphony Connect, the next generation of automated nucleic acid purification platform, to be shown at AMP 2025 as early access phase begins ahead of full release in mid-2026 QIAGEN showcases Sample to Insight workflows for comprehensive genomic profiling (CGP) based on Element Bioscien...

2025-11-05 15:51:57 ET More on Qiagen Qiagen N.V. (QGEN) Q3 2025 Earnings Call Transcript Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript Qiagen N.V. (QGEN) Presents At Baird Global Healthcare Conference 2025 Transcript ...

2025-11-05 15:51:13 ET Qiagen N.V. (QGEN) Q3 2025 Earnings Call November 5, 2025 9:30 AM EST Company Participants John Gilardi - VP & Head of Corporate Communications Thierry Bernard - CEO, MD & Member of Management Board Roland Sackers - CFO, MD & Memb...

2025-11-04 15:47:17 ET More on Qiagen Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript Qiagen N.V. (QGEN) Presents At Baird Global Healthcare Conference 2025 Transcript Qiagen N.V. (QGEN) Presents At Morgan Stanley 23rd Annu...

Q3 2025 results: Net sales of $533 million (+6% at actual rates); diluted EPS $0.60 Core sales +6% CER (constant exchange rates) driven by QIAstat-Dx (+11% CER), QuantiFERON (+11% CER) and Sample technologies (+3% CER) Solid adjusted operating income margin at 29.6% Adjust...

Parse Biosciences is a fast-growing innovator in single-cell sample preparation, with technologies used in more than 3,000 labs across over 40 countries Acquisition strengthens QIAGEN’s presence in the rapidly growing single-cell market, accelerating growth across its industry-...

Advanced Energy Industries Inc. (AEIS) is expected to report $1.16 for Q3 2025 Neuropace Inc. (NPCE) is expected to report $-0.2 for Q3 2025 Oportun Financial Corporation (OPRT) is expected to report $0.2 for Q3 2025 trivago N.V. (TRVG) is expected to report $0.07 for Q3 2025 Alle...